RxDoctor Payments Data

Peter Hoftiezer, DO

Family Medicine · Chariton, IANPI 1497062558

Payments from drug & device makers

$1,665in general payments, 2019–2025

Across 22 payments — averaging $75.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • Novo Nordisk$121
  • Bayer$73
  • Abbott$42
  • Biohaven Pharmaceutical Holding Company Ltd.$32
  • AbbVie$32
  • plus $164 from 9 others

What the payments were for

  • Consulting fees$1,20072%
  • Food & beverage$46528%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,665 in reported general payments places this provider in the 85th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$12,331
Medicare patients
78
Services billed
195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban130$105,285
TrulicityDulaglutide82$83,930
OzempicSemaglutide46$44,899
JardianceEmpagliflozin53$41,429
MounjaroTirzepatide38$40,318
XareltoRivaroxaban32$36,183
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$21,407
LinzessLinaclotide24$13,925
MyrbetriqMirabegron14$11,002
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$10,431
JanuviaSitagliptin Phosphate14$9,017
Tresiba Flextouch U-100Insulin Degludec18$8,496
Memantine Hcl53$6,404
Breo ElliptaFluticasone/Vilanterol15$6,249
Incruse ElliptaUmeclidinium Bromide17$6,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,200$124,248120 claims
PfizerEliquis$16$105,285130 claims
Novo NordiskOzempic$121$44,89946 claims
Boehringer IngelheimJardiance$14$41,42953 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$15$33,80259 claims
AbbVieLinzess$32$13,92524 claims
MerckJanuvia$15$9,01714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Chariton

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →